Anna Brown

Specialising in cardiovascular disease risk assessment, GENinCode’s products combine genetic and clinical data to risk assess patients and provide doctors with advanced clinical information and genetic insight to predict the onset of cardiovascular disease.

The AIM listing sees the company valued at £42.2 million, raising £17m by way of a placing. This will be used to assist GENinCode as it focuses on achieving US regulatory approval and commercialising its products in the US, further expansion into the EU, and expanding into the UK market.

Led by corporate partner Anna Brown, the Addleshaw Goddard team which supported GENinCode included partner, Murray Jack; associate, Michael Flett; associate, Mhairi Cruikshank; trainee solicitor, Finlay MacDougall; and trainee solicitor, Ashley Thomson.

Ms Brown said: “GENinCode’s admission to AIM underlines the support for the company from investors and the opportunity to improve the current standard of care and enhance the assessment of the risk of the onset of cardiovascular disease which is, globally, the leading cause of death.

“Improving health and the standard of care for cardiovascular disease and reducing the costs associated with this represent a global challenge. GENinCode has the opportunity to make a step change in the assessment of the risk of CVD through its use of genomic precision testing and the IPO will provide an excellent platform to enable GENinCode to drive its ambitious agenda.

“We are delighted to have supported GENinCode at this exciting time. This IPO underlines our expertise both in taking companies to the public markets but also in the healthcare and life science space which has played such a crucial role in the last 18 months as we continue to tackle the COVID-19 pandemic.”

Matthew Walls, CEO of GENinCode, said: “We have worked with Anna Brown and the team at Addleshaw Goddard since our company was established in 2018. They have provided fantastic support and guidance assisting GENinCode with our growth plans, particularly the IPO process and our institutional investment by Maven and Downing last year.”